GO
Loading...

Vivus Inc

More

  • FDA approves Novo Nordisk's injection for obesity Tuesday, 23 Dec 2014 | 5:14 PM ET

    Dec 23- The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans. Saxenda's rivals include Vivus Inc's Qsymia and Arena Pharmaceuticals Inc's Belviq, which are taken orally. A study showed that half the patients given Saxenda lost at least 5...

  • FDA clears Novo Nordisk's weight loss drug Saxenda Tuesday, 23 Dec 2014 | 4:29 PM ET

    NEW YORK— The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. The FDA approved liraglutide in 2010 as a treatment for type 2 diabetes, and Novo Nordisk sells it under the name Victoza as a treatment for that condition. It cleared Vivus Inc.' s Qsymia and Arena Pharmaceuticals Inc.' s Belviq in 2012 and granted...

  • Dec 19- European regulators recommended the approval of Orexigen Therapeutics Inc's diet pill, which could become the first prescription medicine for obesity to be approved in the European Union in nearly a decade. The drug, sold as Contrave by partner Takeda Pharmaceutical Co in the United States, will be marketed as Mysimba in Europe. The third obesity...

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.

  • NEW YORK, Sept 18- U.S. stocks were higher in afternoon trading on Thursday, with the S&P 500 hitting a record peak a day after the U.S.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • US STOCKS-Dow, S&P hit record as financials climb Thursday, 18 Sep 2014 | 1:14 PM ET

    NEW YORK, Sept 18- U.S. stocks were higher in afternoon trading Thursday, with the Dow and S&P 500 hitting fresh record highs after the U.S. Goldman Sachs, up 1.6 percent to $187.84, was the top boost to the Dow.

  • US STOCKS-S&P hits record on Fed support; financials lead Thursday, 18 Sep 2014 | 11:42 AM ET

    NEW YORK, Sept 18- U.S. stocks were rising in late morning trading on Thursday, with the S&P 500 hitting a record high a day after the U.S. However, the central bank's outlook included forecasts for higher-than-expected rates in 2015 and 2016, which helped financial stocks lead gains on Wall Street.

  • The largest percentage gainer on the New York Stock Exchange was Penn West Petroleum, up 11.54 percent, while the largest decliner was Pier 1 Imports, down 17.57 percent a day after it slashed its full-year earnings forecast.

  • *Futures up: Dow 44 pts, S&P 6 pts, Nasdaq 13 pts. NEW YORK, Sept 18- U.S. stocks were set to rise at the open on Thursday, with the S&P 500 on track to test resistance at its record high a day after the U.S.

  • Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.

  • Here's a new way to lose weight Thursday, 11 Sep 2014 | 8:08 AM ET

    U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.

  • Long-awaited diet pill gets U.S. approval Wednesday, 10 Sep 2014 | 9:00 PM ET

    Sept 10- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

  • WASHINGTON, Sept 9- Novo Nordisk's drug liraglutide appears effective in treating obesity, though safety questions remain, according to a preliminary assessment by reviewers at the U.S. Food and Drug Administration.

  • You’ve got obesity all wrong: Zafgen CEO Tuesday, 19 Aug 2014 | 10:45 AM ET

    Despite the fact that more than a third of U.S. adults are obese, it's been an uphill battle for developers of obesity treatments.

  • Lightning Round: Akamai, GE & more Tuesday, 15 Jul 2014 | 6:49 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Orexigen shares hit by FDA delay in obesity drug Wednesday, 11 Jun 2014 | 10:07 AM ET

    Orexigen Therapeutics shares fell 15 percent after the FDA delayed its decision on the drug pending post-marketing safety monitoring requirements.

  • Orexigen shares plunge on FDA diet-drug delay Wednesday, 11 Jun 2014 | 7:33 AM ET

    Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.

  • Obesity game-changer? Why this time it's different Monday, 9 Jun 2014 | 12:45 PM ET

    An FDA decision on Orexigen's obesity drug, Contrave, is expected Wednesday, and analysts say its late arrival on market may help.